

Anti-Integrin alpha 4 [Natalizumab] Standard Size Ab00716-23.0

Recombinant monoclonal antibody to Integrin alpha 4. Manufactured using AbAb's Recombinant Platform with variable regions (i.e. specificity) from the therapeutic antibody Natalizumab.

Isotype and Format: Rabbit IgG, Kappa

Clone Number: Natalizumab

Alternative Name(s) of Target: CD49D; alpha 4 subunit of VLA-4 receptor; ITGA4; Integrin alpha-IV

UniProt Accession Number of Target Protein: P13612

Published Application(s): Block, FC

Published Species Reactivity: Human

Immunogen: The RAMOS cell line, a non-EBV releasing cell line, injected into mice.

Specificity: This antibody binds to the alpha 4 binds subunit of $\alpha 4\beta 1$ (also known as very late antigen 4 [VLA-4] or CD49d-CD29) and $\alpha 4\beta 7$ integrin

Application Notes: This antibody binds to human integrin alpha 4 and has been used to treat Multiple Sclerosis and Crohn's Disease.

Antibody First Published in: Sheremata et al. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS Neurology. 1999 Mar 23;52(5):1072-4. [PMID:10102433](#)

Note on publication: Describes the safety and pharmacokinetic characterization of this antibody in a clinical setting.

Product Form

Size: 200 µg Purified antibody.

Purification: Protein A affinity purified

Supplied In: PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.